The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review

CER6307
2013 Vol.31, N°2 ,Suppl.76
PI 0122, PF 0134
Review

Free to view
(click on article PDF icon to read the article)

PMID: 23910616 [PubMed]

Received: 26/01/2013
Accepted : 06/05/2013
In Press: 23/07/2013
Published: 23/07/2013

Abstract

OBJECTIVES:
Interleukin-6 (IL-6) may play a role in the pathogenesis of SSc. C-reactive protein (CRP), an acute phase reactant induced by IL-6, may be a prognostic marker in SSc. The goal of this systematic review was to address the significance and clinical application of IL-6 and CRP in systemic sclerosis (SSc).
METHODS:
A literature search was conducted to identify English-language original articles within PubMed, Scopus, and Medline database from inception to May 30, 2013 using keywords `systemic sclerosis or scleroderma and C-reactive protein or interleukin-6`.
RESULTS:
The search resulted in 156 relevant articles. Some single nucleotide polymorphisms and gene-gene interactions affect SSc predisposition, manifestation and expression of IL-6. Studies in animal models show IL-6 and IL-6 trans-signalling are involved in SSc disease development. Derangements of T and B cells function regulate IL-6 in SSc pathogenesis. Fibroblasts, T/B cells, monocytes, macrophages, dendritic cells and endothelial cells participate in IL-6 expression and interact with each other resulting in tissue sclerosis. Up-regulation of serum IL-6 and CRP levels are evident in SSc patients and associated with disease activity, severity, disability, worse outcome and reduced survival. Targeted IL-6 therapy in SSc has occurred in small cases series and within a multi-site trial that is under way.
CONCLUSIONS:
Studies show IL-6 and CRP are important in SSc both in pathogenesis and clinical manifestations and may be useful indicators of disease activity, severity, and poor prognosis. IL-6 could be a relevant treatment target in SSc.